Market news

Denali Therapeutics (DNLI) has an average rating of buy and mean price target of $34.88, according t

Denali's Avlayah launch drives strong uptake and a 33.1% three-month stock gain, but regulatory and pipeline risks remain.

Detailed price information for Denali Therapeutics Inc (DNLI-Q) from The Globe and Mail including charting and trades.

Denali Therapeutics (DNLI) is transitioning from a neuroscience platform to a commercial biotech with AVLAYAH, its FDA-approved rare-disease therapy.

Denali Therapeutics (DNLI) has an average rating of buy and mean price target of $34.88, according t

Motley Fool Press Release.

Denali Therapeutics (DNLI) is scheduled to present at the Alzheimer’s Association International Conference in London on July 12, 2026, where CEO Ryan J. Watts will be speaking. The event is drawing renewed attention to the stock. See our latest analysis for Denali Therapeutics. The upcoming AAIC presentation sits against a backdrop where Denali Therapeutics’ share price has climbed 45.30% year to date and its 1 year total shareholder return of 63.37% contrasts with weaker 3 and 5 year total...

Detailed price information for Denali Therapeutics Inc (DNLI-Q) from The Globe and Mail including charting and trades.

Denali Therapeutics stock has delivered a 71.8% return over the past year, yet current valuation checks suggest the shares are trading at a premium, with both the Discounted Cash Flow (DCF) intrinsic value estimate and market multiples pointing to an overvalued picture. A 71.8% one year return sets a high bar for future expectations and can leave less room for disappointment in the share price. The recent FDA approval of Avlayah and positive analyst coverage may support higher revenue...

Denali Therapeutics gains FDA approval for Avlayah, but pipeline setbacks and partner exits raise fresh questions as key clinical programs continue.

Denali co-founder and CEO Ryan Watts, Ph.D., to deliver opening plenary address at 2026 AAIC in London on July 12, 2026Presentation will highlight recent...

Denali Therapeutics surges on Avlayah???s FDA approval, PRV sale and pipeline progress, but partnership changes and trial setbacks remain in focus.